Ashraf A. Noah
@ashraf-noah.bsky.social
PharmD, MSc in Pharmacology, PhD Candidate in Pharmacology | Harvard Med School Associate Alumni
☆ My last post:
I joined Bluesky hoping to build research collaborations, but visibility here is too limited and even videos don’t work properly. The platform needs a lot of improvement, so I’m uninstalling the app.
If you’d like to connect, here’s my LinkedIn: www.linkedin.com/in/ashraf-al...
I joined Bluesky hoping to build research collaborations, but visibility here is too limited and even videos don’t work properly. The platform needs a lot of improvement, so I’m uninstalling the app.
If you’d like to connect, here’s my LinkedIn: www.linkedin.com/in/ashraf-al...
www.linkedin.com
October 9, 2025 at 8:50 AM
☆ My last post:
I joined Bluesky hoping to build research collaborations, but visibility here is too limited and even videos don’t work properly. The platform needs a lot of improvement, so I’m uninstalling the app.
If you’d like to connect, here’s my LinkedIn: www.linkedin.com/in/ashraf-al...
I joined Bluesky hoping to build research collaborations, but visibility here is too limited and even videos don’t work properly. The platform needs a lot of improvement, so I’m uninstalling the app.
If you’d like to connect, here’s my LinkedIn: www.linkedin.com/in/ashraf-al...
Working on pharmacology, clinical research, and healthcare innovation. Who’s up for collaboration?
#Pharmacology #ClinicalResearch #Collaboration
#Pharmacology #ClinicalResearch #Collaboration
October 4, 2025 at 11:07 AM
Working on pharmacology, clinical research, and healthcare innovation. Who’s up for collaboration?
#Pharmacology #ClinicalResearch #Collaboration
#Pharmacology #ClinicalResearch #Collaboration
☆ Pleased to share my paper in the European Journal of Pharmacology:
Empagliflozin reverses liver fibrosis & portal hypertension via Gal-1/NRP-1/TGF-β and VEGFR2 pathways, suggesting a novel antifibrotic approach.
Link: www.sciencedirect.com/science/arti...
#Pharmacology #Liver #Empagliflozin
Empagliflozin reverses liver fibrosis & portal hypertension via Gal-1/NRP-1/TGF-β and VEGFR2 pathways, suggesting a novel antifibrotic approach.
Link: www.sciencedirect.com/science/arti...
#Pharmacology #Liver #Empagliflozin
Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways
To date, liver fibrosis has no clinically approved treatment. Empagliflozin (EMPA), a highly selective sodium-glucose-cotransporter-2 (SGLT2) inhibito…
www.sciencedirect.com
September 28, 2025 at 7:29 PM
☆ Pleased to share my paper in the European Journal of Pharmacology:
Empagliflozin reverses liver fibrosis & portal hypertension via Gal-1/NRP-1/TGF-β and VEGFR2 pathways, suggesting a novel antifibrotic approach.
Link: www.sciencedirect.com/science/arti...
#Pharmacology #Liver #Empagliflozin
Empagliflozin reverses liver fibrosis & portal hypertension via Gal-1/NRP-1/TGF-β and VEGFR2 pathways, suggesting a novel antifibrotic approach.
Link: www.sciencedirect.com/science/arti...
#Pharmacology #Liver #Empagliflozin
Reposted by Ashraf A. Noah
WHO statement on autism-related issues
The World Health Organization (WHO) emphasizes that there is currently no conclusive scientific evidence confirming a possible link between #autism and use of acetaminophen (also known as paracetamol) during pregnancy
Full statement bit.ly/47YsgwI
The World Health Organization (WHO) emphasizes that there is currently no conclusive scientific evidence confirming a possible link between #autism and use of acetaminophen (also known as paracetamol) during pregnancy
Full statement bit.ly/47YsgwI
September 24, 2025 at 8:16 AM
WHO statement on autism-related issues
The World Health Organization (WHO) emphasizes that there is currently no conclusive scientific evidence confirming a possible link between #autism and use of acetaminophen (also known as paracetamol) during pregnancy
Full statement bit.ly/47YsgwI
The World Health Organization (WHO) emphasizes that there is currently no conclusive scientific evidence confirming a possible link between #autism and use of acetaminophen (also known as paracetamol) during pregnancy
Full statement bit.ly/47YsgwI
☆ Calling fellow pharmacologists!
I’m looking to connect and collaborate on research projects in neuropharmacology and cardiovascular pharmacology.
If you are open to joint work, let’s connect and explore potential collaborations.
#Pharmacology #Research #Collaboration
I’m looking to connect and collaborate on research projects in neuropharmacology and cardiovascular pharmacology.
If you are open to joint work, let’s connect and explore potential collaborations.
#Pharmacology #Research #Collaboration
September 24, 2025 at 7:40 PM
☆ Calling fellow pharmacologists!
I’m looking to connect and collaborate on research projects in neuropharmacology and cardiovascular pharmacology.
If you are open to joint work, let’s connect and explore potential collaborations.
#Pharmacology #Research #Collaboration
I’m looking to connect and collaborate on research projects in neuropharmacology and cardiovascular pharmacology.
If you are open to joint work, let’s connect and explore potential collaborations.
#Pharmacology #Research #Collaboration
☆ Thrilled to share my new review published in Naunyn-Schmiedeberg's Archives of Pharmacology:
“New Frontiers in Pharmacological Treatment of Attention-Deficit Hyperactivity Disorder.”
▪︎Link: link.springer.com/article/10.1...
“New Frontiers in Pharmacological Treatment of Attention-Deficit Hyperactivity Disorder.”
▪︎Link: link.springer.com/article/10.1...
New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder - Naunyn-Schmiedeberg's Archives of Pharmacology
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. This manuscript reviews the current understanding of ADHD...
link.springer.com
September 23, 2025 at 8:02 AM
☆ Thrilled to share my new review published in Naunyn-Schmiedeberg's Archives of Pharmacology:
“New Frontiers in Pharmacological Treatment of Attention-Deficit Hyperactivity Disorder.”
▪︎Link: link.springer.com/article/10.1...
“New Frontiers in Pharmacological Treatment of Attention-Deficit Hyperactivity Disorder.”
▪︎Link: link.springer.com/article/10.1...
☆ Excited to share that my co-authored research has been published in the European Journal of Pharmaceutical Sciences:
“Intranasal Empagliflozin Modulates Synaptic Plasticity in Migraine: Insights into Calcium Signaling and Epigenetic Regulation.”
Link: www.sciencedirect.com/science/arti...
“Intranasal Empagliflozin Modulates Synaptic Plasticity in Migraine: Insights into Calcium Signaling and Epigenetic Regulation.”
Link: www.sciencedirect.com/science/arti...
Intranasal empagliflozin modulates synaptic plasticity in migraine: Insights into calcium signaling and epigenetic regulation
Migraine is a primary headache disorder without a definite pathophysiology or satisfactory managing strategies. Recently, migraine is primarily a diso…
www.sciencedirect.com
September 23, 2025 at 6:49 AM
☆ Excited to share that my co-authored research has been published in the European Journal of Pharmaceutical Sciences:
“Intranasal Empagliflozin Modulates Synaptic Plasticity in Migraine: Insights into Calcium Signaling and Epigenetic Regulation.”
Link: www.sciencedirect.com/science/arti...
“Intranasal Empagliflozin Modulates Synaptic Plasticity in Migraine: Insights into Calcium Signaling and Epigenetic Regulation.”
Link: www.sciencedirect.com/science/arti...